Athersys (NASDAQ:ATHX – Get Free Report) and iBio (NASDAQ:IBIO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.
Volatility and Risk
Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Profitability
This table compares Athersys and iBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Athersys | N/A | N/A | -223.03% |
| iBio | N/A | -53.86% | -46.48% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Athersys | $146,000.00 | 0.00 | -$72.53 million | ($2.03) | N/A |
| iBio | $400,000.00 | 207.41 | -$18.38 million | ($0.58) | -2.88 |
iBio has higher revenue and earnings than Athersys. iBio is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings for Athersys and iBio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Athersys | 0 | 0 | 0 | 0 | 0.00 |
| iBio | 1 | 0 | 4 | 3 | 3.13 |
iBio has a consensus target price of $5.00, suggesting a potential upside of 199.40%. Given iBio’s stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than Athersys.
Institutional & Insider Ownership
19.4% of Athersys shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
iBio beats Athersys on 10 of the 13 factors compared between the two stocks.
About Athersys
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.
